# US 2014/0271467 A1 · Probes and methods of imaging non-hodgkins lymphoma

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0271467 A1
- Document ID: US20140271467A1
- Status: Published application
- Kind: A1
- Application number: 14/204,039
- Filed: 2014-03-11
- Published: 2014-09-18
- Earliest claimed: 2013-03-12
- Assignees: The Board of Trustees of the Leland Stanford Junior University
- Applicants: The Board of Trustees of the Leland Stanford Junior University
- Inventors: Benjamin Hackel; Arutselvan Natarajan; Sanjiv S. Gambhir
- Web page: https://patentgrep.com/patent/US20140271467A1

## CPC

- A61K 51/088: {conjugates with carriers being peptides, polyamino acids or proteins (antibodies A61K51/10)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Embodiments of the present disclosure provide for labeled probes such as a 64Cu-FN3 probe (FN3 refers to fibronectin type 3 domain); methods of making labeled probes; pharmaceutical compositions including labeled probes; methods of using labeled probes; methods of diagnosing, localizing, monitoring, and/or assessing non-Hodgkin's lymphoma, cancers, tumors, precancerous cells, and related biological events using labeled probes; kits for diagnosing, localizing, monitoring, and/or assessing non-Hodgkin's lymphoma, cancers, tumors, precancerous cells, and related biological events; and the like.

## Claims

### Claim 1

A method of diagnosing the presence of a non-Hodgkin's lymphoma in a subject, the method comprising:
administering to the subject a labeled probe with a sequence comprising a modified FN3 protein scaffold, wherein the probe binds to a CD20 protein;
imaging at least a portion of the subject; and
detecting the labeled probe, wherein the location of the labeled probe corresponds to the location of the non-Hodgkin's lymphoma.

### Claim 2 (depends on 1)

The method of claim 1, wherein the labeled probe includes a sequence having SEQ ID NO: 2.

### Claim 3 (depends on 2)

The method of claim 2, wherein the labeled probe includes a metal selected from: 64Cu, 89Zr, 86Y, or 68Ga, and is conjugated with the sequence.

### Claim 4 (depends on 3)

The method of claim 3, wherein the metal is conjugated to the sequence via a lysine amino acid or a N-terminus free amine site.

### Claim 5 (depends on 3)

The method of claim 3, wherein at least two metals are conjugated to the sequence.

### Claim 6 (depends on 3)

The method of claim 3, wherein the metal is conjugated to the sequence using a chelator selected from the group consisting of: DOTA, NOTA, EDTA, Df, DTPA, and TETA.

### Claim 7 (depends on 6)

The method of claim 6, wherein the metal is 64Cu and the chelator is DOTA.

### Claim 8 (depends on 2)

The method of claim 2, wherein the metal is 64Cu and is conjugated to the sequence via a lysine amino acid or a N-terminus free amine site.

### Claim 9

A method of monitoring the progress of a non-Hodgkin's lymphoma in a subject, the method comprising:
administering to the subject a labeled probe with a sequence comprising a modified FN3 protein scaffold, wherein the probe binds to a CD20 protein;
imaging at least a portion of the subject; and
detecting the labeled probe, wherein the location of the labeled probe corresponds to the location of the non-Hodgkin's lymphoma, wherein the dimensions of the location are monitored over time.

### Claim 10 (depends on 9)

The method of claim 9, further comprising repeating the steps of claim 9 periodically to monitor the dimensions of the location corresponding to the non-Hodgkin's lymphoma.

### Claim 11 (depends on 9)

The method of claim 9, wherein the labeled probe includes a sequence having SEQ ID NO: 2.

### Claim 12 (depends on 11)

The method of claim 11, wherein the labeled probe includes a metal selected from: 64Cu, 89Zr, 86Y, or 68Ga, and is conjugated with the sequence.

### Claim 13 (depends on 12)

The method of claim 12, wherein the metal is conjugated to the sequence via a lysine amino acid or a N-terminus free amine site.

### Claim 14 (depends on 12)

The method of claim 12, wherein at least two metals are conjugated to the sequence.

### Claim 15 (depends on 12)

The method of claim 12, wherein the metal is conjugated to the sequence using a chelator selected from the group consisting of: DOTA, NOTA, EDTA, Df, DTPA, and TETA.

### Claim 16 (depends on 15)

The method of claim 15, wherein the metal is 64Cu and the chelator is DOTA.

### Claim 17 (depends on 11)

The method of claim 11, wherein the metal is 64Cu and is conjugated to the sequence via a lysine amino acid or a N-terminus free amine site.

### Claim 18

A method of screening for an agent for treating a non-Hodgkin's lymphoma in a sample, the method comprising:
contacting the sample with a labeled probe with a sequence comprising a modified FN3 protein scaffold, wherein the probe binds to a CD20 protein, wherein a non-Hodgkin's lymphoma is present in the sample;
contacting an agent with the sample;
imaging at least a portion of the sample; and
detecting the labeled probe, wherein the location of the labeled probe corresponds to non-Hodgkin's lymphoma, wherein the size of the location is monitored over time.

### Claim 19 (depends on 18)

The method of claim 18, wherein the labeled probe includes a sequence having SEQ ID NO: 2.

### Claim 20 (depends on 18)

The method of claim 18, wherein the labeled probe includes a metal that is conjugated to the sequence using a chelator selected from the group consisting of: DOTA, NOTA, EDTA, Df, DTPA, and TETA.

### Claim 21 (depends on 20)

The method of claim 20, wherein the metal is 64Cu and the chelator is DOTA.

### Claim 22 (depends on 20)

The method of claim 20, wherein the metal is 64Cu and is conjugated to the sequence via a lysine amino acid or a N-terminus free amine site.

### Claim 23

A probe, comprising: a labeled probe, wherein the labeled probe includes a sequence having SEQ ID NO: 2.

### Claim 24 (depends on 23)

The probe of claim 23, wherein the labeled probe includes a metal selected from: 64Cu, 89Zr, 86Y, or 68Ga, is conjugated with the sequence.

### Claim 25 (depends on 24)

The probe of claim 24, wherein the metal is conjugated to the sequence via a lysine amino acid or a N-terminus free amine site.

### Claim 26 (depends on 24)

The probe of claim 24, wherein the metal is conjugated to the sequence using a chelator selected from the group consisting of: DOTA, NOTA, EDTA, Df, DTPA, and TETA

### Claim 27 (depends on 26)

The probe of claim 26, wherein the metal is 64Cu and the chelator is DOTA.

### Claim 28 (depends on 24)

The probe of claim 24, wherein the metal is 64Cu and is conjugated to the sequence via a lysine amino acid or a N-terminus free amine site.

### Claim 29

A pharmaceutical composition, comprising:
a pharmaceutical carrier and an effective dose of a labeled probe with a sequence comprising a modified FN3 protein scaffold, wherein the probe binds to CD20 proteins.

### Claim 30 (depends on 29)

The pharmaceutical composition of claim 29, wherein the labeled probe includes SEQ ID NO: 2.
